Yukiko Tadokoro
University of Tokushima
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yukiko Tadokoro.
The Journal of Medical Investigation | 2016
Miyuki Kanematsu; Masami Morimoto; Masako Takahashi; Junko Honda; Yoshimi Bando; Takuya Moriya; Yukiko Tadokoro; Misako Nakagawa; Hirokazu Takechi; Takahiro Yoshida; Hiroaki Toba; Mitsuteru Yoshida; Aiichiro Kajikawa; Akira Tangoku; Issei Imoto; Mitsunori Sasa
Background Overdiagnosis in mammography (MMG) is a problem. Combination of MMG and ultrasonography for breast cancer screening may increase overdiagnosis. Most cases of overdiagnosis are low-grade ductal carcinoma in situ (LGD), but no reports have focused on them. Materials and methods We immunostained 169 ductal carcinoma in situ (DCIS) cases for ER, PgR, HER2 and Ki67 and classified them into 4 subtypes: ER(+)/HER2(-), ER(+)/HER2(+), ER(-)/HER2(-) and ER(-)/HER2(+). The Ki67 index was used to evaluate the grade of malignancy and examined for correlations with each ER/HER2 subtype and the nuclear grade (NG), with/without comedo necrosis. Results The Ki67 index correlated significantly with NG, both with/without comedo necrosis, and reliably evaluated the grade of malignancy. The index for ER(+)/HER2(-) (n=117, 69.2%) was 7.45±7.10, which was significantly lower than for each of the other types. The index was 5.71±6.94 for ER(+)/HER2(-) without comedo necrosis (n=52, 30.8%), which was significantly lower than with comedo necrosis. This was considered LGD, characterized by absence of microcalcification in MMG and either presence of a solid mass or cystic lesion or absence of hypoechoic areas in ultrasound. Conclusion In Japan, ER(+)/HER2(-) without comedo necrosis accounts for about 30% of DCIS and is LGD. This may be being overdiagnosed. J. Med. Invest. 63: 192-198, August, 2016.
Breast Journal | 2018
Kazuaki Nakashima; Takayoshi Uematsu; Takashi Sugino; Kaoru Takahashi; Seiichirou Nishimura; Yukiko Tadokoro; Tomomi Hayashi
We investigated the radiologic‐pathologic correlation of a strong hypointense rim on T2‐weighted images (T2‐hypo‐rim) surrounding breast mass lesions and evaluated its clinical significance. We retrospectively reviewed 3503 consecutive breast magnetic resonance imaging (MRI) examinations. The T2‐hypo‐rim was defined as a border of strong hypointensity compared with the fat signal on fat‐suppressed T2‐weighted images. Detected lesions with T2‐hypo‐rim were classified as a solid or cystic mass with MRI and correlated with histopathologic findings. Sixty‐two masses (2%; 34 solid, 28 cystic) with T2‐hypo‐rim were detected [44 breast cancers, 18 benign lesions, including 15 (24%) papillary tumors]. Patients with cancer were significantly older than those with benign lesions (P = .002). Breast cancers were significantly larger than benign masses (P = .023). In 49 of 62 lesions (24 solid and 16 cystic cancers; three solid and six cystic benign masses), the rims were accurately correlated with the histopathologic findings. All malignant and benign cystic masses exhibited hemosiderin deposits in the cyst walls. However, 22 of 24 solid cancers and no solid benign masses exhibited hemosiderin at the tumor periphery (92% and 0%, respectively, P < .001). In addition, a thick fibrous capsule was present in nine (38%) of 24 solid cancers and none of the solid benign lesions. Strong T2‐hypo‐rims mostly correlated with hemosiderin deposits and/or sometimes fibrous capsules. Although the rims could not distinguish malignant from benign cystic lesions, they indicated malignancy in solid mass lesions on MRI. Additionally, the rims often indicated papillary tumors.
Breast Cancer | 2018
Kazuaki Nakashima; Takayoshi Uematsu; Kaoru Takahashi; Seiichirou Nishimura; Yukiko Tadokoro; Tomomi Hayashi; Takashi Sugino
BackgroundBreast cancer growth is generally expected to differ between tumor subtypes. We aimed to evaluate tumor doubling time (DT) using ultrasonography and verify whether each tumor subtype has a unique DT.MethodsThis retrospective study included 265 patients with invasive breast cancer who received serial ultrasonography between diagnosis and surgery. Tumor diameters were measured in three directions and DTs were calculated according to an exponential growth model using the volume change during serial ultrasonography. We investigated the relationships between DT, tumor subtype, and histopathological factors.ResultsVolumes did not change in 95 (36%) of 265 tumors and increased in 170 (64%) tumors during serial ultrasonography (mean interval, 56.9 days). The mean volume increases of all tumors and volume-increased tumors were 22.1% and 34.5%, respectively. Triple-negative tumors had greater volume increases (40% vs. 20%, p = 0.001) and shorter DT (124 vs. 185 days, p = 0.027) than estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)– tumors. Volume-increased tumors had higher Ki-67 indices than those of volume-stable tumors in ER+/HER2− (p = 0.002) and ER+/HER2+ tumors (p = 0.011) and higher histological grades in all tumors except triple-negative tumors (p < 0.001). Triple-negative tumors with DTs < 90 days (short-DT) showed higher Ki-67 indices than those with DTs > 90 days (long-DT) (p = 0.008). In ER+/HER2− tumors, histological grades were higher for short-DT than for long-DT tumors (p = 0.022).ConclusionDifferences in tumor DT depending on breast cancer subtype, Ki-67 index, and histological grade were confirmed using serial ultrasonography even during preoperative short interval.
Breast Cancer | 2014
Akiko Ogiya; Kumiko Tanaka; Yukiko Tadokoro; Mariko Kikutani; Takayoshi Uematsu; Hiroya Kashiwagi; Masako Kasami; Kaoru Takahashi
Breast Cancer | 2011
Takayoshi Uematsu; Masako Kasami; Junichiro Watanabe; Kaoru Takahashi; Seiji Yamasaki; Kumiko Tanaka; Yukiko Tadokoro; Akiko Ogiya
Breast Cancer | 2016
Mohamed Mokhtar; Yukiko Tadokoro; Misako Nakagawa; Masami Morimoto; Hirokazu Takechi; Kazuya Kondo; Akira Tangoku
Breast Cancer | 2016
Misako Nakagawa; Masami Morimoto; Hirokazu Takechi; Yukiko Tadokoro; Akira Tangoku
Breast Cancer | 2012
Takayoshi Uematsu; Masako Kasami; Kaoru Takahashi; Junichiro Watanabe; Seiji Yamasaki; Kumiko Tanaka; Yukiko Tadokoro; Akiko Ogiya
Breast Cancer | 2015
Akiko Ogiya; Kaoru Takahashi; Mutsumi Sato; Yoshiko Kubo; Noriko Nishikawa; Mariko Kikutani; Yukiko Tadokoro; Kumiko Tanaka; Takayoshi Uematsu; Junichiro Watanabe; Masako Kasami; Seiji Yamasaki
Skin Cancer | 2017
Kosuke Yoshimi; Tatsuya Shiomi; Hisao Kawahara; Masaki Otsuka; Shusuke Yoshikawa; Yoshio Kiyohara; Tomomi Hayashi; Yukiko Tadokoro; Seiichiro Nishimura; Kaoru Takahashi; Akiko Ishii; Takashi Sugino